FP-1305 (bexmarilimab)
Phase 1/2Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedAbout FP-1305 (bexmarilimab)
FP-1305 (bexmarilimab) is a phase 1/2 stage product being developed by Faron Pharmaceuticals for Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT03733990. Target conditions include Cancer.
Hype Score Breakdown
Clinical
13
Activity
8
Company
2
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03733990 | Phase 1/2 | Completed |
Competing Products
20 competing products in Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| E7389 | Eisai | Phase 1 | 33 |
| Veliparib | AbbVie | Phase 2 | 52 |
| AK-105 | Akeso | Phase 1 | 32 |
| XL820 | Exelixis | Phase 1 | 30 |
| Lymphoseek | Navidea Biopharmaceuticals | Phase 3 | 69 |
| Lymphoseek | Navidea Biopharmaceuticals | Phase 3 | 69 |
| ALT-P7 (HM2-MMAE) | Alteogen | Phase 1 | 33 |
| pegylated liposomal doxorubicin (PLD) + PD-1 | CSPC Pharmaceutical Group Limited | Phase 2 | 51 |
| Biomarkers blood, urine and microbiota samples | Eli Lilly | Pre-clinical | 23 |
| gemcitabine + paclitaxel + bevacizumab | Eli Lilly | Phase 2 | 52 |
| pemetrexed | Eli Lilly | Phase 2 | 52 |
| LY3300054 + Prexasertib | Eli Lilly | Phase 1 | 33 |
| BBP-398 with nivolumab | BridgeBio Pharma | Phase 1 | 30 |
| Cetuximab + Oxaliplatin + Capecitabine | Eli Lilly | Phase 2 | 52 |
| Necitumumab + Gemcitabine + Carboplatin | Eli Lilly | Phase 2 | 52 |
| Gemcitabine + Adriamycine + Paclitaxel | Eli Lilly | Phase 2 | 52 |
| Selpercatinib | Eli Lilly | Pre-clinical | 23 |
| Pemetrexed + Cisplatin + Placebo + Pemetrexed | Eli Lilly | Phase 3 | 77 |
| NBTXR3 activated by IMRT only + NBTXR3 activated by Brachytherapy & IMRT | Nanobiotix | Phase 1/2 | 36 |
| NBTXR3 | Nanobiotix | Phase 1/2 | 36 |